APOH
APOH (apolipoprotein H), also known as beta-2-glycoprotein 1, beta-2-glycoprotein I, BG or B2G1, is a secreted plasma protein that binds negatively charged substances such as heparin and phospholipids. It is a component of circulating plasma lipoproteins and the main autoantigen in antiphospholipid syndrome. Browse Assay Genie's current range of APOH research reagents below, or read on for the biology behind the target.
APOH binds a range of negatively charged substances, including heparin, phospholipids and dextran sulfate. It may prevent activation of the intrinsic blood coagulation cascade by binding to phospholipids on the surface of damaged cells. The protein has been implicated in several physiological pathways, including lipoprotein metabolism, coagulation, haemostasis and the production of antiphospholipid autoantibodies.
The APOH gene encodes a secreted protein that circulates in plasma as a component of lipoproteins. HGNC places it in the apolipoproteins group and in the sushi domain containing group. Orthologues of the gene are designated Apoh in both mouse and rat, which allows the biology to be studied in rodent models.
The protein is historically named apolipoprotein H (beta-2-glycoprotein I), and the abbreviation beta-2-GPI is common in the clinical literature. APOH may be a required cofactor for anionic phospholipid binding by the antiphospholipid autoantibodies found in the sera of many patients with lupus and primary antiphospholipid syndrome (APS). Anti-beta-2 glycoprotein I antibodies from APS patients mediate inhibition of activated protein C, which has anticoagulant properties. Because beta-2-GPI is the main autoantigen in APS, disruption of this pathway by autoantibodies may be an important mechanism underlying thrombosis in these patients.
Beta-2-glycoprotein I is the main autoantigen in APS, and may be a required cofactor for phospholipid binding by antiphospholipid autoantibodies.
APOH may prevent activation of the intrinsic coagulation cascade by binding phospholipids on the surface of damaged cells.
Autoantibodies against beta-2-GPI inhibit activated protein C, a pathway that may contribute to thrombosis in APS patients.
As a component of circulating plasma lipoproteins, APOH has been implicated in lipoprotein metabolism.
APOH binds negatively charged substances such as heparin, phospholipids and dextran sulfate. It may prevent activation of the intrinsic blood coagulation cascade by binding phospholipids on damaged cell surfaces. It has also been linked to lipoprotein metabolism, haemostasis and the production of antiphospholipid autoantibodies.
APOH is the HGNC symbol for apolipoprotein H. The protein is also called beta-2-glycoprotein 1 or beta-2-glycoprotein I (beta-2-GPI), and the aliases BG and B2G1 appear in the literature. The earlier HGNC name was apolipoprotein H (beta-2-glycoprotein I).
Beta-2-GPI is the main autoantigen in antiphospholipid syndrome. Autoantibodies against it, found in many patients with lupus and primary APS, inhibit activated protein C, which may be an important mechanism of thrombosis. Mouse and rat both carry an Apoh orthologue; check the datasheet of any product for its validated reactivity.
Other apolipoproteins, coagulation proteins and phospholipid-binding markers relevant to antiphospholipid syndrome research.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P02749; product specifications from Assay Genie datasheets.